Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C7H7ClN2O4S
CAS Number:
Molecular Weight:
250.66
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
InChI
1S/C7H7ClN2O4S/c8-4-2-5(9)3(7(11)12)1-6(4)15(10,13)14/h1-2H,9H2,(H,11,12)(H2,10,13,14)
SMILES string
Nc1cc(Cl)c(cc1C(O)=O)S(N)(=O)=O
InChI key
QQLJBZFXGDHSRU-UHFFFAOYSA-N
grade
pharmaceutical primary standard
API family
furosemide
manufacturer/tradename
USP
mp
267 °C (dec.) (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
Looking for similar products? Visit Product Comparison Guide
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Furosemide Related Compound B USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
hcodes
Hazard Classifications
Aquatic Chronic 2
Storage Class
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
pcodes
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Thin-layer chromatographic determination of furosemide and 4-chloro-5-sulfamoyl anthranilic acid in plasma and urine.
B Wesley-Hadzija et al.
Journal of chromatography, 229(2), 425-432 (1982-05-14)
F Andreasen et al.
Acta pharmacologica et toxicologica, 49(3), 223-229 (1981-09-01)
Three principles for the use of HPLC with spectrophotometric detection to determine the concentration of furosemide and of 4-chloro-5-sulfamoyl anthranilic acid (CSA) were studied. A reversed phase microbondapack C18 column was used for the separation of either unchanged furosemide (I)
H Nakahama et al.
Nephron, 53(2), 138-141 (1989-01-01)
Furosemide is known to potentiate gentamicin nephrotoxicity. The mechanism of potentiation is unclear. In our previous studies, we demonstrated that furosemide enhanced gentamicin accumulation in rabbit renal tissues when injected as a bolus [Kidney int. 33:363, 1988] or repeatedly subcutaneously
The binding of furosemide to serum proteins in elderly patients: displacing effect of phenprocoumon.
F Andreasen et al.
Acta pharmacologica et toxicologica, 47(3), 202-207 (1980-09-01)
The percentual binding of furosemide (5 micrograms/ml) was slightly but significantly lower in serum from elderly patients than in serum from normal blood donors (96.5 +/- 0.7 versus 97.9 +/- 0.3). A significant positive correlation was demonstrated between protein binding
D E Smith et al.
Drug metabolism and disposition: the biological fate of chemicals, 8(5), 337-342 (1980-09-01)
The objectives of this study were to qualitatively and quantitatively compare the metabolism, pharmacokinetics, and bioavailability of furosemide in healthy volunteers after intravenous and oral administration. We also determined the plasma protein binding of furosemide in vivo after iv administration.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service